WWARN Study Groups: our latest findings
The WWARN Network has initiated a series of pooled analyses of individual patient data to assess the risk factors associated with recurring malaria infection after treatment with the three main ACTs; artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP).